KEYNOTE-033: Phase 3 study of pembrolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (NSCLC)

被引：0
|
作者：
Zhou, C. [1 ]
Caglevic, C. [2 ]
Zhou, J. [3 ]
Wang, B. [4 ]
Wang, K. [5 ]
Ge, J. [6 ]
Zhou, Y. [6 ]
Piperdi, B. [7 ]
Ma, Z. [8 ]
机构：
[1] Shanghai Pulm Hosp, Dept Oncol, Shanghai, Peoples R China
[2] FALP, Dept Oncol, Santiago, Chile
[3] Zhejiang Univ, Hosp 1, Dept Respirat, Hangzhou, Zhejiang, Peoples R China
[4] Subei Peoples Hosp, Dept Oncol, Yangzhou, Jiangsu, Peoples R China
[5] Zhejiang Univ, Hosp 2, Dept Respirat, Hangzhou, Zhejiang, Peoples R China
[6] MSD China, Oncol, Shanghai, Peoples R China
[7] Merck & Co Inc, Oncol, Kenilworth, NJ USA
[8] Henan Canc Hosp, Dept Oncol, Zhengzhou, Henan, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
466TiP
引用
收藏
页码：143 / 143
页数：1
相关论文
共 50 条
  • [11] Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer
    Maruyama, Riichiroh
    Nishiwaki, Yutaka
    Tamura, Tomohide
    Yamamoto, Nobuyuki
    Tsuboi, Masahiro
    Nakagawa, Kazuhiko
    Shinkai, Tetsu
    Negoro, Shunichi
    Imamura, Fumio
    Eguchi, Kenji
    Takeda, Koji
    Inoue, Akira
    Tomii, Keisuke
    Harada, Masao
    Masuda, Noriyuki
    Jiang, Haiyi
    Itoh, Yohji
    Ichinose, Yukito
    Saijo, Nagahiro
    Fukuoka, Masahiro
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (26) : 4244 - 4252
  • [12] Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)
    Rogado, J.
    Pacheco-Barcia, V.
    Fenor De la Maza, M. D.
    Serra, J. M.
    Toquero, P.
    Vera, B.
    Obispo, B.
    Mondejar, R.
    Ballesteros, A.
    Donnay, O.
    Colomer, R.
    Sanchez-Torres, J. M.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1915 - S1916
  • [13] Randomized, open-label phase III study of pembrolizumab (pembro) vs docetaxel (doce) in patients (pts) with previously treated NSCLC with PD-L1 tumour proportion score (TPS) ≥1%: KEYNOTE-033
    Zhou, C.
    Feng, J.
    Ma, S.
    Chen, H.
    Ma, Z.
    Huang, C.
    Zhang, L.
    He, J.
    Wang, C.
    Zhou, J.
    Danchaivijtr, P.
    Huang, H-C.
    Vynnychenko, I. O.
    Wang, K.
    Orlandi, F.
    Sriuranpong, V.
    Li, B.
    Ge, J.
    Dang, T.
    ANNALS OF ONCOLOGY, 2020, 31 : S816 - S816
  • [14] Phase II study of docetaxel and cisplatin in patients with previously untreated metastatic non-small-cell lung cancer
    Okamoto H.
    Watanabe K.
    Segawa Y.
    Ichinose Y.
    Yokoyama A.
    Yoneda S.
    Niitani H.
    International Journal of Clinical Oncology, 2000, 5 (5) : 316 - 322
  • [15] Phase III Study Comparing Nab-Paclitaxel With Docetaxel in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer
    Nakamura, A.
    Yoneshima, Y.
    Morita, S.
    Ando, M.
    Iwasawa, S.
    Yoshioka, H.
    Goto, Y.
    Takeshita, M.
    Harada, T.
    Hirano, K.
    Oguri, T.
    Kondo, M.
    Miura, S.
    Hosomi, Y.
    Kato, T.
    Kubo, T.
    Kishimoto, J.
    Yamamoto, N.
    Nakanishi, Y.
    Okamoto, I.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S107 - S108
  • [16] Phase II study of docetaxel monotherapy in elderly patients with advanced non-small-cell lung cancer (NSCLC)
    Takigawa, N
    Segawa, Y
    Kishino, D
    Fujiwara, K
    Shinkai, T
    Watanabe, Y
    Tabata, M
    Kiura, K
    Ueoka, H
    Tanimoto, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 776S - 776S
  • [17] Phase II pharmacodynamic trial of erlotinib in previously treated patients with advanced non-small-cell lung cancer (NSCLC):: Study results
    Felip, Enriqueta
    Rojo, Frederico
    Reck, Martin
    Heller, Astrid
    Klughammer, Barbara
    Maacke, Heiko
    Mocks, Joachim
    Brennscheidt, Ulrich
    Gatzemeier, Ulrich
    Baselga, Jose
    ANNALS OF ONCOLOGY, 2006, 17 : 235 - 235
  • [18] A phase IINCCTG study of irinotecan and docetaxel in previously treated patients with non-small cell lung cancer
    Molina, Julian R.
    Nikcevich, Daniel
    Hillman, Shauna
    Geyer, Susan
    Drevyanko, Timothy
    Jett, James
    Verdirame, Joseph
    Tazelaar, Henry
    Rowland, Kendrith
    Wos, Edward
    Kutteh, Leila
    Nair, Suresh
    Fitch, Tom
    Flynn, Patrick
    Stella, Philip
    Adjei, Alex A.
    CANCER INVESTIGATION, 2006, 24 (04) : 382 - 389
  • [19] EVEROLIMUS PLUS ERLOTINIB VERSUS ERLOTINIB ALONE IN PREVIOUSLY TREATED PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC)
    Bennouna, J.
    Besse, B.
    Leighl, N. B.
    Blais, N.
    Traynor, A. M.
    Papadimitrakopoulou, V.
    Klimovsky, J.
    Jappe, A.
    Jehl, V.
    Johnson, B. E.
    ANNALS OF ONCOLOGY, 2010, 21 : 140 - 140
  • [20] A randomized, open-label, phase III trial comparing amrubicin versus docetaxel in patients with previously treated non-small-cell lung cancer
    Yoshioka, H.
    Katakami, N.
    Okamoto, H.
    Iwamoto, Y.
    Seto, T.
    Takahashi, T.
    Sunaga, N.
    Kudoh, S.
    Chikamori, K.
    Harada, M.
    Tanaka, H.
    Saito, H.
    Saka, H.
    Takeda, K.
    Nogami, N.
    Masuda, N.
    Harada, T.
    Kitagawa, H.
    Horio, H.
    Yamanaka, T.
    Fukuoka, M.
    Yamamoto, N.
    Nakagawa, K.
    ANNALS OF ONCOLOGY, 2017, 28 (02) : 285 - 291
12345